zilebesiran (ALN-AGT) / Alnylam, Roche 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
zilebesiran (ALN-AGT) / Alnylam, Roche
2021-001248-82: A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients with Mild-to-Moderate Hypertension (KARDIA-1)

Not yet recruiting
2
375
Europe
zilebesiran, ALN-AGT01, Solution for injection
Alnylam Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc.
Hypertension, Hypertension, Diseases [C] - Cardiovascular Diseases [C14]
 
 
KARDIA-1, NCT04936035 / 2021-001248-82: A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension

Completed
2
394
Europe, Canada, US, RoW
Placebo, ALN-AGT01, Zilebesiran
Alnylam Pharmaceuticals, Alnylam Pharmaceuticals, Inc.
Hypertension
04/23
12/24
KARDIA-2, NCT05103332 / 2021-003776-13: Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication

Completed
2
672
Europe, Canada, US
Olmesartan, Amlodipine, Indapamide, Placebo, Zilebesiran, ALN-AGT01
Alnylam Pharmaceuticals
Hypertension
12/23
09/24
KARDIA-3, NCT06272487: Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications

Recruiting
2
390
Europe, Canada, US, RoW
Zilebesiran, ALN-AGT01, Placebo
Alnylam Pharmaceuticals
High Cardiovascular Risk, Hypertension
03/25
12/25
ALN-AGT01-006, NCT06423352: A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension

Active, not recruiting
1/2
36
Japan
Zilebesiran, ALN-AGT01, Placebo
Alnylam Pharmaceuticals
Mild to Moderate Hypertension
09/25
09/25
NCT06675565: A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers

Recruiting
1
78
Canada
ALN-AGT01 RVR, Placebo
Alnylam Pharmaceuticals
Healthy Volunteers
09/25
09/25

Download Options